Jerad Shoemaker MD

Psychiatrist and Writer | Basics of Psychiatry | Future of the physical exam | Medical systems & AI.

An evidence-based look at agents in development, new clinical resources, and papers gaining traction this cycle

Sep 18, 2026

•

7 min read

An evidence-based look at agents in development, new clinical resources, and papers gaining traction this cycle

Late-stage candidates, updated site references, and the research clinicians are reading now.

Jerad Shoemaker MD

A closer look at the approval story, new clinical resources, and papers drawing attention this cycle.

Sep 11, 2026

•

7 min read

A closer look at the approval story, new clinical resources, and papers drawing attention this cycle.

Mechanism, evidence, site updates, and the papers clinicians are discussing now.

Jerad Shoemaker MD

Regulatory developments and access challenges shaping prescribing, with site updates and high-interest papers from the past six months

Sep 4, 2026

•

7 min read

Regulatory developments and access challenges shaping prescribing, with site updates and high-interest papers from the past six months

Policy and regulatory changes with direct clinical implications, plus the papers getting traction.

Jerad Shoemaker MD

What is advancing toward approval, new clinical resources, and papers gaining traction this cycle

Aug 28, 2026

•

7 min read

What is advancing toward approval, new clinical resources, and papers gaining traction this cycle

Pipeline drugs worth watching and recent papers

Jerad Shoemaker MD

Agents approaching approval, a closer look at a key clinical scale, and the origins of a modern diagnosis.

Aug 22, 2026

•

5 min read

Agents approaching approval, a closer look at a key clinical scale, and the origins of a modern diagnosis.

Where late-stage agents stand, how to use the scale reliably, and the history behind the diagnosis.

Jerad Shoemaker MD

Pipeline drugs, site updates, and recent papers

Aug 14, 2026

•

6 min read

Pipeline drugs, site updates, and recent papers

What is advancing toward approval, new clinical resources, and the papers attracting attention this cycle

Jerad Shoemaker MD

New approvals, site updates, and recent papers

Aug 8, 2026

•

6 min read

New approvals, site updates, and recent papers

A closer look at the approval story, new clinical resources, and papers drawing attention this cycle

Jerad Shoemaker MD

Generic availability, a drug-class comparison, and a discovery origin story

Jul 31, 2026

•

5 min read

Generic availability, a drug-class comparison, and a discovery origin story

Where the supply chain stands, how two agents compare head-to-head, and the serendipitous path that brought a drug class to market.

Jerad Shoemaker MD

Jul 24, 2026

•

5 min read

Newly Approved Medications

July 23rd, 2026 newsletter

Jerad Shoemaker MD

Psychiatric pipeline, adverse-event profiles, and how psychiatric science works

Jul 17, 2026

•

6 min read

Psychiatric pipeline, adverse-event profiles, and how psychiatric science works

Compounds nearing approval, a close look at tolerability data, and the methodology shaping psychiatric evidence.

Jerad Shoemaker MD

Jul 11, 2026

•

5 min read

Policy & FDA Watch

CMS Medicaid frailty exemption now requires psychiatric documentation

Jerad Shoemaker MD

Generic availability, adverse-effect profiles, and diagnostic history

Jul 3, 2026

•

6 min read

Generic availability, adverse-effect profiles, and diagnostic history

Jerad Shoemaker MD

Candidates advancing through trials, how two treatments compare on evidence, and the legal milestones that shaped prescribing today.

Jun 26, 2026

•

5 min read

Candidates advancing through trials, how two treatments compare on evidence, and the legal milestones that shaped prescribing today.

Pipeline drugs, a head-to-head comparison, and the legal past behind it

Jerad Shoemaker MD

New approvals, mechanisms of action, and psychiatric research methods

Jun 19, 2026

•

5 min read

New approvals, mechanisms of action, and psychiatric research methods

What cleared regulatory review, how the agents work at a receptor level, and how psychiatric science builds its evidence base.

Jerad Shoemaker MD

FDA policy shifts, adverse-event profiles, and legal history in psychiatry

Jun 12, 2026

•

5 min read

FDA policy shifts, adverse-event profiles, and legal history in psychiatry

Regulatory updates, a close look at tolerability data, and the legal precedents that shaped current practice.

Jerad Shoemaker MD

Drug supply disruptions, rating scale utility, and psychiatric research methodology

Jun 5, 2026

•

6 min read

Drug supply disruptions, rating scale utility, and psychiatric research methodology

Where generic shortages stand, how to apply common rating scales at the bedside, and what shapes the evidence psychiatry relies on.

Jerad Shoemaker MD

Psychiatric pipeline agents, mechanisms of action, and drug discovery history

May 29, 2026

•

5 min read

Psychiatric pipeline agents, mechanisms of action, and drug discovery history

What is advancing toward approval, how the pharmacology works, and the path that brought a key compound to clinic.

Jerad Shoemaker MD

What got approved this cycle, how the comparators stack up, and how the diagnostic category came to be

May 22, 2026

•

5 min read

What got approved this cycle, how the comparators stack up, and how the diagnostic category came to be

New FDA approvals, antipsychotic comparisons, and diagnostic history

Jerad Shoemaker MD

Generic shortages, mechanism deep-dive, and a legal history worth knowing

May 16, 2026

•

6 min read

Generic shortages, mechanism deep-dive, and a legal history worth knowing

From supply chain gaps to receptor-level pharmacology and the courtroom decisions behind current prescribing law.

Jerad Shoemaker MD

Psychiatric pipeline drugs, rating scale review, and diagnostic history

May 8, 2026

•

5 min read

Psychiatric pipeline drugs, rating scale review, and diagnostic history

What is advancing through trials, how key rating scales perform in practice, and the origins of a modern diagnosis.

Jerad Shoemaker MD

New FDA approvals, adverse-effect profiles, and drug discovery origins

May 1, 2026

•

5 min read

New FDA approvals, adverse-effect profiles, and drug discovery origins

A look at what cleared approval, what the side-effect data actually show, and how a landmark compound came to exist.

Jerad Shoemaker MD

Apr 26, 2026

•

6 min read

Generic availability, adverse-effect profiles, and diagnostic history

Where supply stands on key generics, what the adverse-event data actually show, and how a diagnosis took its current shape.

Jerad Shoemaker MD

Apr 17, 2026

•

5 min read

Pyschopharmref weekly

Pipeline Drugs, Medication Comparison, HIstorical/Legal Context

Jerad Shoemaker MD

Mar 17, 2026

•

3 min read

Welcome

Welcome to the Psychopharmacology Reference Newsletter

Jerad Shoemaker MD